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Biosensors enable observation and understanding of latent physiological occurrences
otherwise unknown or invasively detected.Wearable biosensors monitoring physiological
constructs across a wide variety of mental and physical health conditions have become
an important trend in innovative research methodologies. Within substance use research,
explorations of biosensor technology commonly focus on identifying physiological
indicators of intoxication to increase understanding of addiction etiology and to inform
treatment recommendations. In this review, we examine the state of research in this
area as it pertains to treatment of alcohol use disorders specifically highlighting the
gaps in our current knowledge with recommendations for future research. Annually,
alcohol use disorders affect approximately 15 million individuals. A primary focus of
existing wearable technology-based research among people with alcohol use disorders
is identifying alcohol intoxication. A large benefit of wearable biosensors for this purpose
is they provide continuous readings in a passive manner compared with the gold
standard measure of blood alcohol content (BAC) traditionally measured intermittently
by breathalyzer or blood draw. There are two primary means of measuring intoxication
with biosensors: gait and sweat. Gait changes have been measured via smart sensors
placed on the wrist, in the shoe, and mobile device sensors in smart phones. Sweat
measured by transdermal biosensors detects the presence of alcohol in the blood stream
correlating to BAC. Transdermal biosensors have been designed in tattoos/skin patches,
shirts, and most commonly, devices worn on the ankle or wrist. Transdermal devices
were initially developed to help monitor court-ordered sobriety among offenders with
alcohol use disorder. These devices now prove most useful in continuously tracking
consumption throughout clinical trials for behavioral treatment modalities. More recent
research has started exploring the uses for physical activity trackers and physiological
arousal sensors to guide behavioral interventions for relapse prevention. While research
has begun to demonstrate wearable devices’ utility in reducing alcohol consumption
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among individuals aiming to cutdown on their drinking, monitoring sustained abstinence
in studies exploring contingency management for alcohol use disorders, and facilitating
engagement in activity-based treatment interventions, their full potential to further aid in
understanding of, and treatment for, alcohol use disorders has yet to be explored.
Keywords: wearable biosensors, alcohol use disorder, treatment, transdermal alcohol content, contingency
management
INTRODUCTION
In the United States, each year, alcohol use disorders (AUD)
affect roughly 15 million individuals and cost nearly $250 billion
in treatment and economic losses (1, 2). An estimated 7% of
people who need treatment for AUD ever receive it resulting
in staggering mortality and morbidity (2). Treatment options
include outpatient therapy, intensive outpatient programs, and
inpatient admission with detoxification, with each approach
increasing in costs, patient time demands, and disrupting quality
of life. Advances in technology have the potential to significantly
improve these barriers to treatment (3). Research using novel
technology to address public health problems has increased
exponentially in the twenty first century. Broadly known as
digital health, this area of research explores the use of mobile
and computer software applications and wearable biosensor
devices to better understand and treat health conditions (4–9).
Within research on AUD, the use of biosensors specifically has
become an important trend in innovative researchmethodologies
(3). Biosensor devices enable observation and understanding
of latent physiological occurrences otherwise unknown or
invasively detected. Wearable biosensors are placed externally
on the body and typically measure movement, sweat or skin
conductance, heart rate, or temperature (9). In AUD biosensor
research literature, devices tested fall into two categories:
(1) those designed specifically to detect alcohol use (e.g.,
identifying intoxication) and (2) those designed for primarily
other purposes (e.g., physical activity) but are being explored
in specific use cases related to alcohol. The former has a
significantly larger body of literature, with most research
over the past 20 years centering on creating and refining
biosensors to detect intoxication in laboratory and field-testing
environments (10–13).
Recent reviews on wearable biosensors for alcohol use have
provided in-depth looks into the mechanics of how specific
biosensors work (14), the status of biosensor development
ranging from prototype to commercial availability (15, 16), the
benefits and pitfalls of different devices (14, 16), and implications
for how numerous sensors can be used to improve research on
pharmacotherapy and interactions with alcohol use (17). In this
review, we will summarize the use of wearable biosensors in
clinical research of AUD treatments. We will (1) provide a brief
introduction to the various types of alcohol-specific biosensor
devices currently available that hold potential for uses in AUD
treatment research, (2) examine in-depth how wearables devices
are being used in clinical research to improve existing or provide
novel approaches to AUD treatment, and (3) highlight the gaps in
current knowledge and consider implications for future research.
The overall goal of this review is to examine how researchers
are utilizing existing wearable technologies in treatments
for AUD.
MEASURING INTOXICATION
There are two primary means of measuring intoxication with
biosensors: gait and sweat. Gait is measured by locomotion on
three axes—forward/backward, side-to-side, up and down, and
ground reaction forces—the impact of the force of the foot as
it hits the ground. Using machine learning algorithms, patterns
of movement are mapped onto known blood alcohol content
(BAC) levels measured by blood draws or breathalyzer to better
understand how people move at various levels of intoxication. A
recent development in locomotion research with alcohol has even
mapped patterns of movement with machine learning algorithms
to determine when someone is holding and lifting the drink
and how long they are taking sips (17). Gait-tracking biosensors
can be worn on the ankle and wrist, inserted in shoes, or
detected by mobile phones typically in the pocket. In addition
to standard gait measurements, with the use of mobile phones,
patterns of engagement with mobile applications (e.g., rate of
typing, number of errors made while typing) on the phones
can also be used to infer intoxication (18). Research using gait
to identify alcohol use first emerged in the literature in 2012
(19), with the bulk of research published within the past 5 years
(20–26). The diverse design and placement of gait-tracking
biosensors may facilitate a burgeoning body of exploration
among AUD treatment samples; however, to date, research using
these biosensors occurs exclusively in non-treatment samples and
contexts. The most common research sample is among college
students, a group known for their risky drinking behaviors, and
the most common purpose is to prevent drinking and driving
(27). The nascent status of using gait measuring devices and
complex algorithms to understand alcohol use likely contributes
to why these types of sensors have yet to be used in AUD
treatment research.
Sweat, including interstitial fluid that exists between cells
containing sweat glands, is measured by transdermal devices that
electronically analyze biomarkers in vapors on the surface of
the skin and secretions inside the dermis. As alcohol emanates
from the bloodstream and diffuses through the skin, transdermal
devices detect the amount of alcohol in sweat and interstitial
fluid that then algorithmically correlates to BAC measured by
blood draw or breathalyzer (28–30). Additional algorithms have
been tested to further align transdermal alcohol levels with
standard drink units (30). Since the chemical makeup of sweat
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can differ for each individual, measuring transdermal alcohol
content requires a baseline reading absent of any consumed
alcohol. Transdermal alcohol readings have approximately a 30-
min lag between consumption and detection compared with
breath-based readings (28–30). Biosensors measuring changes
in skin temperature and heart rate variability can supplement
sweat and gait data to improve detection of alcohol consumption
(17). Coupled with GPS-based location data, these physiological
data points can be used to determine proximity to places where
someone might socially consume alcohol or purchase alcohol.
While many of the sweat-based devices have been validated
using samples of people in AUD treatment, the focus of those
studies was not treatment related, but rather ensuring that the
devices accurately captured higher levels of BAC seen in this
population compared with the community. In treatment studies
using transdermal devices, the purposes focus on (1) comparing
findings to traditional alcohol use measurement (i.e., patient self-
report or use of breathalyzer, blood draws, or urine analysis),
(2) using the alcohol use data to inform intervention efforts,
or (3) assessing acceptability and feasibility of using the device
while in AUD treatment. Table 1 provides an overview of devices
measuring gait and sweat to detect alcohol intoxication.
ALCOHOL-SPECIFIC BIOSENSORS
The Secure Continuous Remote Alcohol Monitor (SCRAM R©) is
the most widely used wearable device in clinical research trials
and has been adopted internationally by justice systems for court-
monitored sobriety. The SCRAM R© is an ankle worn monitor
that electrochemically measures transdermal alcohol content.
The device takes measurements roughly once every half hour
and more frequently when a heavy drinking episode is detected
or tampering is suspected. The measurements result in three
alcohol-related outcomes: (1) total transdermal alcohol content
reported as grams of alcohol per deciliter of sweat (g/dl), (2)
absorption rate or how quickly alcohol appears in the sweat
reported as g/dl per hour, and (3) elimination rate or how quickly
alcohol leaves the sweat also reported as g/dL per hour. The
measurements are stored on the device and uploaded via wired or
wireless connection onto a secure web-based server that provides
reports on transdermal alcohol and other measurements. The
device can be worn continuously and contains features that deter
removal and that detect potential tampering, which triggers an
alert and investigation to confirm/disprove.
Technology like SCRAM R© has made it possible to advance
AUD research and treatment in ways not previously possible.
For example, contingency management (CM) is an efficacious
substance use disorder treatment that has been difficult to apply
to AUD because of the need to objectively verify abstinence.
Contingency management, based on principles of learning and
behavioral economics, is a program of systematically reinforcing
(incentivizing) objective evidence of pro-health target behaviors
to improve outcomes, such as reinforcing abstinence to improve
substance use disorder treatment outcomes. There is robust
evidence supporting improvements in abstinence and harm
reduction with CM (32–34). Few studies have assessed CM for













































































AUD because the most common objective measure of alcohol
consumption is the alcohol breath test, which has a small window
of detection (hours) and thus usually requires either several in-
person tests per day to detect all use, or if used clinically, occurs
too infrequently to detect alcohol use between treatment sessions.
Now, transdermal alcohol sensing technology allows for remote
objective monitoring of alcohol use near continuously, and CM
research incorporating this technology is occurring.
Barnett et al. (35) conducted the first pilot using wearable
biosensors with a CM intervention to change alcohol
consumption behaviors. This study utilized a sample of 13
individuals in the community who reported heavy drinking
habits (≥8 drinks per week for women, ≥15 for men) with an
interest in reducing alcohol consumption. Participants wore the
SCRAM R© monitor and self-reported alcohol use for 3 weeks. The
first week was an observation period where no CM intervention
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was provided, and drinking patterns were just reported. In weeks
2 and 3 of the study, monetary reinforcement was provided
for each day when no alcohol use was detected by SCRAM R©.
Alcohol use detection was defined by one transdermal alcohol
reading >0.02 g/dl, and either an absorption rate <0.05 g/dl
per hour for a single drinking episode or an elimination rate
<0.025 g/dl per hour (when peak <0.15 g/dl) and > 0.035 g/dl
per hour (when peak >0.15 g/dl) for a single drinking episode.
For the initial day with no alcohol use detected, participants
received $5, and each consecutive day per week with no alcohol
detection, monetary reinforcement increased by $2, consistent
with CM best practices and research (36). At the end of the
3-week study period, there were significant increases in the
number of days abstinent in week 2 and 3 compared with the
1-week observation period (p< 0.001) and significant reductions
in the average transdermal alcohol content across all days
indicating a reduction in the number of drinks consumed each
sitting (p < 0.01). Barnett et al. (37) built upon these findings
by conducting a second study among a similar sample (N = 30)
using the same CM schedule and SCRAM R© criteria for earning
monetary reinforcement. In addition to the drinks per week
inclusion criteria used in the aforementioned study, this study
also required individuals to have two or more heavy drinking
episodes per week (>3 for women, >4 for men in one sitting)
to be eligible to participate. Furthermore, the CM intervention
period was increased from 2 to 3 weeks, and they added a
1-month follow-up period to track progress once CM was
removed. During the follow-up period, participants did not wear
the SCRAM R© bracelet and self-reported alcohol use during that
timeframe. Participants were randomized to either a CM group
or a non-contingent reinforcement group (controls) in which
monetary compensation was yoked to reinforcement earned
by a matched CM participant and not contingent on drinking
status. Compared with the controls, participants in the CM
group had a higher percentage of device-derived abstinent days
(p= 0.05) and longer periods of device-derived consecutive days
without drinking detected (p = 0.03) during the 3 intervention
weeks. At the end of the 1 month follow-up period, there were
no differences between groups on the number of consecutive
days without drinking. These findings suggest that monetary
incentives linked to transdermal alcohol readings can reduce
risky alcohol consumption while incentives are available.
Dougherty et al. (38–40) also used SCRAM R© in several CM
studies aimed at reducing the amount of alcohol consumed
weekly by community-based heavy drinkers defined as>3 drinks
for women or>4 drinks for men in one sitting at least three times
in the last 28 days. Unlike the aforementioned Barnett et al. (35)
study, these studies used a harm reduction approach, meaning
that rather than requiring abstinence, participants received
monetary reinforcement for days with alcohol consumption
not exceeding 0.03 g/dl levels on three consecutive SCRAM R©
measurements. This threshold was chosen as transdermal levels
> 0.03 g/dl typically correspond to light to moderate drinking
(one to two beers) (28). In the first study, 26 at-risk drinkers
(defined above) were randomized to one of two groups that
varied in the timing of CM for scientific purposes. When
provided, monetary reinforcement for each group was delivered
once a week and was earned when participants did not exceed
0.03 g/dl in any single day throughout the past week. In
Group A, participants received no monetary reinforcement for
4 weeks followed by 4 weeks of $25 monetary reinforcement
per week of no drinking detected. In Group B, the sequence
of the reinforcement was switched, with participants receiving
$25 monetary reinforcement in the first 4 weeks followed by
4 weeks with no monetary reinforcement. After 8 weeks, both
groups then received weekly monetary reinforcements of $50 for
an additional 4 weeks. Results showed significant reductions in
heavy drinking days during the 8-week CM periods compared
with the 4 weeks with no monetary reinforcement (p < 0.001).
Furthermore, drinking reductions did not differ between the $25
per week phase and $50 per week phase, suggesting that the lower
cost program may be a viable option for reducing heavy drinking
(38). Dougherty’s et al. (39, 40) second study expanded upon
the abovementioned findings by increasing the length of CM
period from 2 to 3 months and adding a follow-up period to track
progress once CM was removed. In this study, 82 participants
wore SCRAM R© for a 4-week observation period followed by a 12-
week period with weekly delivered $50 monetary reinforcement
for not exceeding 0.03 g/dl in any single day throughout the
past week. At the end of the 12-week CM period, the SCRAM R©
monitor was removed, and participants were followed up once
monthly for 3 months to self-report alcohol use in the past
28 days. SCRAM R© data demonstrated that participants were
seven times more likely to not exceed the 0.03 g/dl drinking limit
during the CM period compared with the observation period
(p = 0.01). Additionally, using self-report data, the participants
had significantly fewer heavy and moderate (adjusted for sex)
drinking days during both the 12-week CM and 3-month follow-
up period compared with the observation period (p < 0.001),
with participants reporting similar drinking behaviors during
the CM period and the 3 months following discontinuation of
CM (39, 40). Unlike the conclusions from Barnett et al. (37),
this study suggests that reductions in heavy alcohol consumption
with CM for alcohol-negative transdermal alcohol readings may
continue after removal of incentives. The mixed findings may
be attributable to reinforcing abstinence vs. drinking reductions.
Another possible contributing factor is the duration or other
parameters of CM prior to discontinuation of incentives. Future
research is needed to better understand the mixed results.
Two studies have reported on SCRAM R© among AUD
treatment patients (41, 42). In both studies, all participants
received standard community-based AUD treatment services
including group therapy, 12-Step, and relapse prevention
approaches. Alessi et al. (42) reported on the feasibility and
acceptability of monitoring from the initial 100 participants in
one of two randomized control trials of 12-weeks of SCRAM R©
monitoring of alcohol consumption and CM for either AUD
treatment attendance or CM for each day of SCRAM R©-
based no drinking among community-based outpatient AUD
treatment patients. They found that relatively few patients
declined to participate in the study because of the SCRAM R©
monitoring aspect (<10%), and the majority (84%) provided
SCRAM R© data every day of the 12-week treatment period. Most
participants reported neutral comfort with the bracelet, denied
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the bracelet interfered with their mood, sleep, work, and normal
activities, and believed the bracelet helped them reduce their
drinking. These findings indicate that SCRAM R© may be feasibly
incorporated into outpatient treatment of AUD. Additionally,
Alessi et al. (41) used SCRAM R© to track alcohol use for 3 months
in 63 patients in community-based AUD treatment. SCRAM R©
was used to objectively and near-continuously characterize
individuals’ drinking habits while in outpatient treatment for the
first time. Participants also completed self-reports of drinking
about twice weekly (for research purposes only, and not shared
with clinic staff), and device data were compared with self-
reports to assess the level of agreement. The SCRAM R© data
indicated a higher percentage of patients who drank any alcohol
and drank heavily compared with the percentage who drank
and drank heavily per self-reports. These results suggest that
wearable biosensors may provide clinically useful information
to supplement self-reports, which can be biased by response
demands and other contextual factors (42–44). Throughout the
study, clinicians were not provided access to SCRAM R© data;
thus, they were not able to use this information to inform
treatment decisions.
PHYSICAL ACTIVITY BIOSENSORS
In addition to wearable devices explicitly designed for alcohol
use, researchers have begun using biosensors originally developed
for other purposes to improve treatments of alcohol use
disorder. Abrantes et al. (45) tested the feasibility of a novel
physical activity intervention using FitBit Charge watches aimed
to prevent relapse in woman with depression going through
alcohol treatment. Twenty women were enrolled from a partial
hospitalization program and were given FitBit Charges and
provided counseling on the benefits of physical activity on
managing cravings and difficult emotions. Participants were
given a list of free/low-cost activities that they could engage
in throughout the 12-week intervention and were each given
a daily step goal that increased by 500 steps each week of
the intervention. Once discharged from the 10-day partial
hospitalization program, they were offered 6, 30-min phone
calls from an activity counselor who addressed barriers to
engaging in physical activity and tailored step goals to meet their
individual needs. Five women did not complete the intervention,
and analyses were conducted using both intention-to-treat and
among completers only to address missing data. Similar results
were seen in both analytic approaches. Among completers only,
44%were abstinent of alcohol throughout the entire intervention,
and on average, women were abstinent on 95% of the days during
the 12 weeks. Participants reported a significant increase in use of
physical activity to improve mood and cope with urges to drink
compared with at the start of the study (p < 0.05). These results
show promise for using physical activity monitored by biosensors
to increase coping strategies for cravings to drink alcohol and
maintain abstinence in those critical months following discharge
from a partial hospitalization program.
Similarly, Linke et al. (46) conducted a feasibility study among
11 veterans in outpatient substance use treatment aimed to
reduce alcohol and illicit drug use through a physical activity
program monitored by FitBit HR (47). Participants completed
a 12-week intervention that provided weekly psychoeducation
groups focused on integrating physical activity for a healthy
lifestyle while reducing substance use and a YMCA membership
with access to group training sessions and a Fit4Me personal
training program. Each participant was given the exercise-related
goals of 150+ min per week of aerobic exercise, 2–3 weekly
strength training activities, and at least 2 weekly flexibility
sessions. Once a week, participants met with a study clinician to
review the FitBit HR data and address any barriers to engaging
in physical activity. At the end of the 12-week intervention,
participants reported a significant change in the number of
days using alcohol each month and number of drinks per day
when drinking (p < 0.001). Participants reported in qualitative
interviews that the FitBit HR helped them be accountable to their
physical activity plan, and that seeing daily and weekly progress
on their physical activity goals helped them stay motivated to
remain abstinent of alcohol and other drugs.
EMOTION-FOCUSED BIOSENSORS
Leonard et al. (47) used the Empatica E4 wristband to monitor
electrodermal activity (e.g., stress or emotional arousal) in
a feasibility study of a mobile application-based mindfulness
intervention for college women referred from the university
counseling center for problem drinking defined as scoring three
or higher on the Alcohol Use Disorders Identification Test—
Consumption (AUDIT-C). Participants (N = 10) in the study
wore the E4 wristband for 1 week before receiving an in-
person counseling session that assessed several factors related to
drinking behaviors (e.g., readiness to change, consequences of
drinking, short-term goals) and their stress and physical activity
in the past week, and setup an alert to activate when the E4
wristband reached an individually determined stress threshold.
For 3 weeks following this session, participants were instructed to
use theMind theMoment mobile application when they received
the stress-related alert. The application guides users through
brief cognitive behavioral and mindfulness strategies (e.g., deep
breathing, meditation, and positive self-talk). Participants were
also encouraged to use the application between E4 stress-related
alerts. In qualitative interviews, 70% of the sample stated that
using the application and wearing the wristband helped them
reduce risky drinking behaviors and adhere to their short-term
drinking goals set in the counseling session. The purpose of the
study was on the feasibility of using a mobile application-based
intervention paired with a wearable biosensor, and quantitative
data on changes in number of drinks per week/month were
not reported.
Additionally, Rouw (48) developed and tested a treatment
protocol integrating Sense-IT biosensor data and associated
mobile application into inpatient alcohol treatment to enable
awareness of physiological processes elicited by arousal,
emotions, and cravings. Sense-IT is an ambulatory biofeedback
mobile application that utilizes heart rate data from a smartwatch
to provide haptic and visual feedback on wearer’s heart rate.
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The biosensor plus associated mobile application was originally
created for patients with Borderline Personality Disorder to
improve emotion awareness and regulation (49). As this specific-
use case of Sense-IT was novel, Rouw explored both providers’
(N = 3) and patients’ (N = 2) input on the potential value of
integrating the technology into existing treatmentmodalities. For
COVID-related logistical reasons, Rouw tested this technology
among addiction treatment inpatients as opposed to ambulatory
care patients as initially planned. For 3 weeks, patient participants
completed structured sessions using guided imagery and Sense-
IT biofeedback with the goal of increasing user’s awareness of
physiological arousal that occurs when experiencing cravings
to drink. During the biofeedback sessions, participants were
given cognitive behavioral therapeutic interventions to cope
with the cravings and see the impact of those interventions on
their physiological arousal. Patient participants reported they
found added value in using Sense-IT to better understand their
cravings and added that it facilitated conversations with the
interventionist about strategies for coping with cravings. They
noted that the technology may be more useful in an outpatient
setting where access to treatment providers is less constant, and
the environment is less controlled. Provider participants also
reported that the Sense-IT could be a useful tool in improving
patients’ awareness of their cravings and cueing them to take
therapeutic action rather than use substances.
DISCUSSION
In treatment studies utilizing wearable biosensors, participants
generally report good feasibility and acceptability of the devices,
suggesting that integration into treatment may be acceptable
among patients. Among the limited number of studies using
wearable technology in AUD treatment contexts, the majority
used these devices to measure alcohol use or abstinence
throughout study periods. With treatments like contingency
management, using wearable devices eliminates the need
for participants to undergo invasive blood draws or use a
breathalyzer during their sessions, which may be more desirable.
Furthermore, recent studies are beginning to expand biosensor
uses to include incorporating physiological data, like heart rate
and number of steps, into the treatment modality. While these
approaches represent advancements with potential to improve
AUD treatment, applications to date have been narrow in scope.
The time is ripe for expansion of novel uses for wearable
biosensors in this domain of clinical research.
There are several important areas related to using wearable
technology to treat individuals with AUD that are yet to
be explored. One is incorporating feedback from transdermal
alcohol content biosensors into other treatment modalities
besides contingency management. Biosensor data could replace
or supplement self-reported alcohol use in behavioral and
cognitive behavioral treatments for AUD and inform more
accurate and tailored treatment recommendations. For example,
based on harm reduction principles, with real-time feedback on
alcohol levels, clinicians and patients in an outpatient setting
could collaboratively set a daily transdermal alcohol content
goal for 1 week at a time with expectations for reducing those
levels to either abstinent or healthy levels over time rather
than abrupt cessation or abstinence. Additionally, clinicians
could review the biosensor data with the patient and help
them understand specific drinking patterns (e.g., quantity, rate
of consumption, and time of consumption) in relation to
specific environmental and social factors and tailor treatment
recommendations and coping strategies based on this data.
Incorporating feedback on alcohol use could similarly be used
with pharmacotherapies that treat AUD. Baseline recordings
of transdermal alcohol content could potentially help guide
dosing decisions for initiation of medication-assisted therapy.
Furthermore, continuous monitoring of numerous physiological
constructs using an additional biosensor like FitBit throughout
pharmacotherapy could highlight interaction effects of alcohol
and other substances on the effectiveness of the medication-
assisted therapy (17).
Incorporating wearable alcohol biosensors into Just-In-Time
Adaptive Interventions (JITAIs) to reduce drinking is another
area for future investigation. These interventions aim to monitor
dynamic states (e.g., of risk of substance use) and provide support
of the right kind, at the right time, and only when needed.
Examples in this growing literature include alcohol research
that combined smartphone sensor data and ambulatory self-
reports of alcohol use to build machine learning models to
predict future high-risk drinking (50). In other work, natural
language processing of online recovery forums and machine
learning techniques were used to build models to automatically
detect potential recovery problems, for potential for intervention
(51). A meta-analysis of JITAI studies (e.g., on diet, mental
health, addiction, and blood glucose control) foundmoderate-to-
large effect sizes with JITAIs compared with control conditions
and non-JITAI interventions (52). Thus, research suggests
that incorporating alcohol biosensors into the development of
effective JITAIs has great potential to advance delivering clinically
meaningful support to individuals where and when needed.
Potential effectiveness of JITAIs could be further enhanced
by using biosensors to better understand and detect craving:
a known phenomenon in individuals with moderate to severe
alcohol use disorder that lacks consensus on definition, factors
influencing it, and assessment (53, 54). Craving is marked
by several physiological (e.g., heart rate, blood pressure,
sweat, saliva) and emotional (e.g., anxiety and dysregulation)
changes that biosensor data and complex machine learning
algorithms may be able to measure and quantify in a clinically
significant way. Intervening in real-time when an individual is
experiencing cravings has important implications for preventing
relapse, particularly in the early stages of treatment (54,
55). While the use of biosensors to detect cravings may
have the greatest synergy with JITAIs, they could easily be
incorporated in a number of treatment modalities to improve
treatment outcomes, including medication-assisted therapies
targeting craving.
An additional area of significant potential is in the
treatment of alcohol withdrawal syndrome. Though many
of the commercially available devices are not specifically
designed to measure withdrawal symptoms, they are capable
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of measuring many physiological symptoms that occur in
alcohol withdrawal (e.g., variable heart rate, proximal sweats,
and changes in temperature). Combining a transdermal alcohol
content device with an additional biosensor that measures
these physiological changes could create an automated detection
for alcohol withdrawal symptoms that drastically improves
upon the existing measurement and treatment of alcohol
withdrawal, including protracted withdrawal where symptoms
can persist for many months subsequent to the immediate
period following abrupt cessation (56). Furthermore, devices
that measure withdrawal symptoms could facilitate an outpatient
treatment protocol for detoxification, reducing the treatment
burden of lengthy inpatient stays. Following detoxification, the
biosensors could then be used in some of the aforementioned
potential treatment modalities for monitoring and informing
outpatient treatment.
In conclusion, wearable biosensors have demonstrated
their utility in improving delivery of cost-effective,
evidence-based treatments for AUD and are currently
being explored in novel ways to further improve AUD
treatment options and access. There are numerous
innovative uses of wearable biosensors yet to be explored
in AUD treatment, and future research should tap into
this potential.
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